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Abstract
Background: Cancer mortality is one of the major causes of productivity loss; and within all cancer sites, malignant
neoplasms of the lung continue to be the principal cancer-related cause of death in Spain, with a survival rate of
only 10.7%. Thus its effects in labour productivity are a major concern and represent a great social impact. The
objective of this study was to evaluate the productivity losses that occur as a result of premature deaths due to
lung cancer in Spain.
Methods: The human capital approach was used to calculate the costs derived from the premature mortality due
to lung cancer, via the extraction of data on mortality, reference salaries and unemployment rates.
Results: Deaths due to lung cancer represented the 28.90% and the 10.83% of all cancer-related deaths in 2017 in
males and females respectively, with an increasing tendency in this last group. In addition, the YPPLL count
increased in the study period among females. Lung cancer was responsible annually for 60,846 YPPLL, and
productivity losses summed €13.1 billion over the 10 year period.
Conclusions: The assessment of productivity losses due to lung cancer provides new information that may assist
decision makers in the allocation of resources, reducing the burden it supposes in working-age individuals.
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Background
Lung cancer is the fourth most prevalent cancer among
males in Spain, the ninth in women, and the leading
cancer-related cause of death in males [1]. Worldwide,
tracheal, bronchus and lung cancers were the leading
cancer-related cause of death for both males and females
in 2013 [2], indeed, in Spain, the 5 year survival rate is
only 10.7% [3].
Lung cancer mortality peaks in individuals aged 75 to
79 years in developed countries as the United Kingdom
[4]; however, worldwide, the highest rates are observed
in males between 60 and 75 years of age [5]. Altogether,
deaths prior 65 years of age have a notorious impact on
economic productivity, in which cancer plays a great role
[6]. In males, cancers of the trachea, bronchus and lung
together were the leading cause of disability-adjusted
life-years (DALYs), which combine health loss with pre-
mature mortality, accounting for 34.7 million DALYs in
2013, 62% of those in developing countries and 38% in
developed countries [2].
Estimations of productivity loss provide valuable data
for informed resource allocation. Distinct approaches are
used to estimate lost productivity. The human capital ap-
proach is the majority method, based on the assumption
that individuals have a potential productivity to their re-
tirement age that is reduced due to illness or death, lead-
ing to losses that can be quantified [7]. Secondarily, the
friction cost approach is centred on the losses that take
place in the time it takes to replace a worker; this method
aims to provide a more realistic calculation, however, it re-
quires the use of a standard measurement of replacement
time [8]. Finally, other methods exist focusing on different
variables, for instance the willingness to pay approach
values immaterial costs as pain and distress [9].
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Altogether, predictions of cancer mortality-related
productivity loss have been projected for various coun-
tries [10, 11]. In Spain, the estimated losses due to can-
cer temporary disability were €248.6 million in 2005
[12], added to the €2.5 billion in losses due to premature
mortality estimated in 2009 [13]. The scale of such costs
demonstrates the extent of the burden of cancer and the
possible economic gains that could be reached by the
implementation of informed policies that reduce the in-
cidence of the cancers causing the most expenses.
The present study aimed to evaluate the losses in
terms of productivity that occur as a result of premature
deaths due to lung cancer in Spain.
Materials and methods
Study design
This study was developed based on the human capital ap-
proach to calculate the costs derived from premature
mortality due to lung cancer, considering the income and
contribution to the nation productivity of an individual
that are prevented when a premature death occurs. This
method was selected taking into account previous studies
in the country, and looking to provide a calculation from
the worker’s perspective.
Mortality data and reference salaries per age group
were obtained from the Spanish National Statistics Insti-
tute (INE) [14, 15]. The years of potential productive life
lost (YPPLLs) due to premature mortality from lung
cancer were estimated by multiplying the number of
lung cancer-specific deaths for a given age group by the
expected productive years remaining for each group. Re-
tirement age was fixed at 65 years.
To obtain an estimation of costs of premature mortal-
ity, age- and sex-specific annual wages from death age to
age of retirement were used. YPPLL was corrected per
age- and gender-specific unemployment rates [16] and
an annual discount rate of 3% was applied to future in-
come values. A sensitivity analysis was conducted con-
sidering two alternative discount rates (0 and 6%).
Results
In total, 212,632 people died of lung cancer in Spain be-
tween 2008 and 2017, 69,225 during working age.
Deaths due to lung cancer represented 28.90% of all
cancer-related deaths in 2017 in males and 10.83% in fe-
males, with an increasing tendency in this last case
(Table 1). The year 2008 displayed the highest number
of YPPLLs for males, 49,654, while the highest number
in females was observed the last year of the study period,
23,035 measured in 2016. Altogether, the average annual
YPPLL count was 60,846.
The year 2017 was considered the reference year in
the analysis of the age distribution of YPPLL. Premature
mortality in the age period between 50 and 59 years
accounted for the highest values of YPPLL (Fig. 1).
The costs of premature mortality were estimated, pro-
jecting productivity losses to retirement years and
adjusting all calculations per age- and sex-specific an-
nual wages. The analysis provided three estimations, a
baseline, and the results of the sensitivity analysis. The
accumulated productivity losses from 2008 to 2017 due
to lung cancer were €13.1 billion (Table 2). The sensitiv-
ity analysis determined a range between €12.8 and €13.5
billion. The amount of losses derived from males was
significantly higher than that derived from women, yet
in both cases losses showed a decreasing tendency over
the study period. The lost productivity measured in
males in 2017 was of €899 million, while in females it
was €284 million.
Productivity losses derived from total cancer-related
mortality were calculated in order to assess this data in
context. Lung cancer accounted for 22.33% of the losses
Table 1 Indicators of deaths, portion of cancer-related deaths attributable to lung cancer and years of potential productive life lost
(YPPLL) due to lung cancer
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Number of deaths
males 17,150 17,279 17,285 17,479 17,661 17,559 17,194 17,239 17,598 17,241
females 3049 3122 3447 3579 3826 4105 4057 4357 4557 4848
Deaths at working age
males 5613 5564 5520 5468 5535 5252 5064 5015 5004 4697
females 1290 1321 1495 1497 1657 1736 1680 1902 1918 1997
% of lung cancer related deaths
males 28.43 26.61 27.94 33.61 26.95 27.59 34.38 25.46 25.65 28.90
females 7.68 8.29 8.39 10.54 9.37 9.75 10.22 9.98 10.91 10.83
YPPLL
males 49,654 47,097 46,225 46,239 46,455 43,281 40,852 40,065 38,757 36,246
females 15,210 15,368 16,430 16,126 17,491 17,708 16,390 18,076 17,754 23,035
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in 2017, and lost productivity derived from lung cancer
peaked the year 2010 when it represented 32.72% of
losses (Fig. 2).
Discussion
Cancer mortality has been pointed out as one of the major
causes of productivity loss [12]. Hence, the increasing
interest on measuring and quantifying its economic and
social impact.
In general calculations, the productivity loss linked to tu-
mours has been estimated to rise up to hundreds of billions
of dollars. The year 2000, the productivity losses associated
with cancer only in the United States summed $116 billion
and were projected to increase to $148 billion in 2020 [6].
Conversely, in Australia, estimations lower this sum to
around $4.2 billion, and 88,000 YPPLLs, presumably an ef-
fect of the smaller population [11]. The same study
remarked lung cancer as one of the malignancies accounting
for the highest portion of costs, in line with former findings
in health loss and premature mortality [2]. Lung cancer is,
in many countries, the most prevalent cancer type
among males, and the principal cancer-related cause
of death [17–19]. A study developed in 30 European
countries, cancer was appointed responsible for losses
of €75 billion, with lung cancer representing 23% of
total costs [18], while another study centred in the
EU measured €126 billion in losses, with lung cancer
representing 15% of the total [19]. In the present
study, losses attributable to lung cancer represented
22.33% of all cancer-related losses in 2017.
Similarly, a revision of data in Spain linked cancer to
43.5% of deaths at working age, accounting for 298,753
YPPLL in 2009 and €2.5 billion in losses [10]. Herein, lung
cancer alone represented 36,246 YPPLL for males and 23,
035 for females in 2017; and its costs summed €1.4 billion
that year, €13.1 billion over a ten year period. The differ-
ences observed in the number of YPPLL between males and
females, as well as the opposed tendencies are presumably
Fig. 1 Years of potential productive life lost (YPPLL) due to premature mortality from lung cancer per age groups in 2017
Table 2 Productivity losses (in millions) of lung cancer (sensitivity models 0%; 6%) and percentage of mortality costs of all diseases
Year Premature mortality costs (baseline) Premature mortality costs (0%) Premature mortality costs (6%)
Males Females Males Females Males Females
2008 1245 319 1278 327 1214 310
2009 1182 244 1213 251 1153 237
2010 1159 228 1190 234 1130 222
2011 1140 219 1170 225 1112 213
2012 1158 174 1189 178 1129 169
2013 1078 170 1107 174 1052 164
2014 1019 164 1045 169 993 161
2015 998 225 1024 231 974 218
2016 963 254 988 261 939 247
2017 899 284 923 291 877 277
Total 10,841 2281 11,126 2342 10,573 2218
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derived from the difference in smoking habits and other
trends that promote an increasing incidence among women
[20]. However, in the calculation of losses, the significantly
different wages for males and females in Spain play an im-
portant role and distort any interpretation of mortality
trends [16].
Interestingly, €2.1 billion in productivity losses were
estimated for women with breast cancer in Spain in
2014 [21], an elevated figure presumably due to the
prevalence of this cancer type in females. It must be
considered that the human capital approach allows an
estimation of losses that provides a general vision of dis-
ease burden, but comparisons among different studies
can become a limitation. In addition, it attributes a
greater weight to deaths affecting young working males,
versus groups with lower employment rates or income,
and thus leading to underestimates and overestimates
[16]; its use is nonetheless generalised in the recent lit-
erature given its efficacy [22].
On the other hand, further considerations including a
calculation of DALYs could be of interest to estimate
the social impact of lung cancer, since early onsets of
the disease may lead primarily to an incapacity for work.
It is interesting to highlight the increasing incidence of
lung cancer-related deaths in females during the study
period, a tendency that has been observed at a global scale
[23] and continues to pose a challenge for researchers.
Nonetheless, a global decreasing tendency of cancer-related
deaths has been described, yet important variations are ob-
served per cancer typology [24]. Such trends must be taken
into consideration for an adjusted distribution of resources.
Equally, the increased years of potential productive life that
are lost by the premature death of workers with ages be-
tween 50 and 59 years are noteworthy in order to develop
adjusted programs.
Conclusions
The assessment of total productivity losses due to lung
cancer provides new information that may assist deci-
sion makers in the allocation of resources. Lung cancer
supposes a significant burden in Spain, with an increas-
ing tendency in women that is reflected in the increasing
number of YPPLL. The promotion of programs aiming
to reduce the incidence of lung cancer in working-age
individuals will presumably yield substantial reductions
in productivity loss counts.
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